


## Online supplementary figure 1 Patient flow



\*Healthy control subjects were screened as part of the diffusion tensor imaging substudy being conducted along with the main study in patients with relapsing-remitting multiple sclerosis. These patients were not treated with natalizumab or fingolimod and were not included in the main study results.

†The safety group comprised all randomised patients who received at least one dose of study drug; the ITT group comprised all randomised patients who received at least one dose of study drug and provided at least one efficacy assessment.

ITT, intent-to-treat.